Your browser doesn't support javascript.
loading
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Pignata, Sandro; Bookman, Michael; Sehouli, Jalid; Miller, Austin; Penson, Richard T; Taskiran, Cagatay; Anderson, Charles; Hietanen, Sakari; Myers, Tashanna; Madry, Radoslaw; Willmott, Lyndsay; Lortholary, Alain; Thomes-Pepin, Jessica; Aghajanian, Carol; McCourt, Carolyn; Stuckey, Ashley; Wu, Xiaohua; Nishio, Shin; Copeland, Larry J; He, Yvette; Molinero, Luciana; Patel, Sheetal; Lin, Yvonne G; Khor, Victor K; Moore, Kathleen N.
Afiliación
  • Pignata S; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) and Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G Pascale, Napoli, Italy. Electronic address: s.pignata@istitutotumori.na.it.
  • Bookman M; Gynecologic Oncology Group Foundation (GOG-F) and Kaiser Permanente Northern California, San Francisco, CA, USA. Electronic address: Michael.A.Bookman@kp.org.
  • Sehouli J; Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (AGO Study Group), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (North-Eastern German Society of Gynaecologic Oncology; NOGGO) and Charité-Medical University of Berlin (Campus Virchow Klinikum), Berlin, Germany. Electronic addr
  • Miller A; GOG-F and Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: Austin.Miller@RoswellPark.org.
  • Penson RT; Massachusetts General Hospital, Boston, MA, USA. Electronic address: Penson.Richard@mgh.harvard.edu.
  • Taskiran C; Turkish Society of Gynecologic Oncology (TRSGO) and Koç University School of Medicine, Istanbul, Turkey; Vehbi Koç Vakfi American Hospital, Istanbul, Turkey. Electronic address: cagataytaskiran@yahoo.com.
  • Anderson C; GOG-F and Willamette Valley Cancer Institute, Eugene, OR, USA. Electronic address: Charles.Anderson@USONCOLOGY.COM.
  • Hietanen S; Nordic Society of Gynaecological Oncology (NSGO), Copenhagen, Denmark and Turku University Hospital, Turku, Finland. Electronic address: Sakari.Hietanen@tyks.fi.
  • Myers T; GOG-F and Baystate Medical Center, Springfield, MA, USA. Electronic address: tashanna.myersmd@baystatehealth.org.
  • Madry R; Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland. Electronic address: radoslaw.madry@skpp.edu.pl.
  • Willmott L; GOG-F and Arizona Oncology Associates, PC, Phoenix, AZ, USA. Electronic address: lyndsay.willmott@arizonaccc.com.
  • Lortholary A; Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein (GINECO) and Hôpital Privé du Confluent, Nantes, France. Electronic address: ALAIN.LORTHOLARY@groupeconfluent.fr.
  • Thomes-Pepin J; GOG-F and Minnesota Oncology, Maplewood, MN, USA. Electronic address: Jessica.ThomesPepin@usoncology.com.
  • Aghajanian C; GOG-F and Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: aghajanc@MSKCC.ORG.
  • McCourt C; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, Saint Louis, MO, USA. Electronic address: cmccourt@wustl.edu.
  • Stuckey A; The Warren Alpert Medical School, Brown University, Providence, RI, USA. Electronic address: AStuckey@Wihri.org.
  • Wu X; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Electronic address: wu.xh@fudan.edu.cn.
  • Nishio S; Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan. Electronic address: shinshin@med.kurume-u.ac.jp.
  • Copeland LJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, USA. Electronic address: Larry.Copeland@osumc.edu.
  • He Y; Global Data Operations, Functional Service Provider, Parexel International, Chengdu, China. Electronic address: yvette.he@businesspartner.roche.com.
  • Molinero L; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA. Electronic address: molinero.luciana@gene.com.
  • Patel S; Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, CA, USA. Electronic address: patel.sheetal@gene.com.
  • Lin YG; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA. Electronic address: lin-liu.yvonne@gene.com.
  • Khor VK; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA. Electronic address: khor.victor@gene.com.
  • Moore KN; GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Sarah Cannon Research Institute, Nashville, TN, USA. Electronic address: Kathleen-Moore@ouhsc.edu.
Gynecol Oncol ; 177: 20-31, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37625235
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Calidad de Vida Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Calidad de Vida Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2023 Tipo del documento: Article